Review · Volume 13, Issue 4 · pp. 711–720
Protein Phosphatase 2A Activation for the Treatment of Alzheimer Disease-Promises and Challenges
Prasenjit Mondal1, Saptarshi Samajdar1, Suman Acharyya2, Sumanta Mondal3
- 1Department of Pharmaceutical Technology, Brainware University, Ramkrishnapur Road, Kolkata, West Bengal, INDIA.
- 2Department of Pharmaceutical Chemistry, Netaji Subhas Chandra Bose Institute of Pharmacy, Tatla, Roypara, Chakdaha, Nadia, West Bengal, INDIA.
- 3Department of Pharmaceutical Chemistry, GITAM School of Pharmacy, GITAM University, Gandhinagar, Rushikonda, Vishakhapatnam, Andhra Pradesh, INDIA.
Abstract
Alzheimer's disease is a progressive brain condition. It is characterized by alterations in the brain that result in the deposition of certain proteins. The brain shrinks and finally dies as a result of Alzheimer's disease. Over the years there has been very concerned efforts to control Alzheimer's disease with strategies like vaccinations but all off them failed in phase three trial. This leads to exploration of new strategy like activation of Protein Phosphatase 2A (PP2A) to control the tau phosphorylation in Alzheimer’s. In this review, a comprehensive review regarding activation of PP2A using drugs like metformin, sphingosides, ceramides, folate and xylulose 5 phosphate, Sodium selenate, Adamantane derivatives, phenolic derivatives, Isoquinolones and Tetralones. Therefore, this approach can offer a fresh glimmer of hope for the treatment of Alzheimer's disease.
Keywords: Protein Phosphatase 2A; Alzheimer's disease; Tau phosphorylation
The full text of this article is available as a PDF. Open the PDF.